Pharmaceutical company Biocad has registered in Russia drug levelmap, designed to combat a complication often associated with coronavirus infection. New drugs were registered according to the accelerated procedure the Decision of the government of the Russian Federation from 03.04.2020. Earlier in the same way was was Aviewer (favipiravir).
According to the manufacturer, levelman is a monoclonal antibody – inhibitor of the receptor for Il-6 (IL-6). Originally a drug created for the treatment of rheumatoid arthritis, but the principle of operation allows it to be used for the relief of the cytokine storm, which during coronavirus infection often leads to the death of patients. Clinical study of the effectiveness of levelimage for additional indications launched on April 24. According to the head of Dmitry Morozov, Biocad, the results of the study demonstrated the ability of the drug to significantly reduce mortality among patients with COVID-19.
KEY levelimage therapy COVID-19 continues, at the present time, it involved 13 medical centers across Russia, including the Bashkir state medical University, City clinical hospital №15 named. O. M. Filatov Moscow, Republican clinical hospital in Dagestan, the Republican clinical hospital named after sh. sh. Alentieva in Chechnya etc.